101 related articles for article (PubMed ID: 11778588)
1. Monitoring clinical trials. Interim data should not be publicly available.
Richards SM
BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11778588
[No Abstract] [Full Text] [Related]
2. Monitoring clinical trials. Several points are contentious.
Parry D
BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778590
[No Abstract] [Full Text] [Related]
3. Monitoring clinical trials. Interim data are at least as important as interim analyses.
Reidpath D
BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778591
[No Abstract] [Full Text] [Related]
4. Monitoring clinical trials. Caution may be warranted in releasing interim trial data.
Thornton H
BMJ; 2001 Dec; 323(7326):1424-5. PubMed ID: 11778589
[No Abstract] [Full Text] [Related]
5. [Interim analyses].
Kramar A; Paoletti X
Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
[TBL] [Abstract][Full Text] [Related]
6. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
Korn EL; Freidlin B
Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
[TBL] [Abstract][Full Text] [Related]
7. Monitoring clinical trials. Dissemination of decisions on interim analyses needs wider debate.
Bird SM
BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11744570
[No Abstract] [Full Text] [Related]
8. Interim monitoring of efficacy data is important and appropriate.
Sydes MR; Parmar MK
J Clin Epidemiol; 2008 Mar; 61(3):203-4. PubMed ID: 18226741
[No Abstract] [Full Text] [Related]
9. The independent statistician for data monitoring committees.
DeMets DL; Fleming TR
Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
[TBL] [Abstract][Full Text] [Related]
10. Regulatory perspectives on data monitoring.
O'Neill RT
Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
[TBL] [Abstract][Full Text] [Related]
11. Futility approaches to interim monitoring by data monitoring committees.
Demets DL
Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
[TBL] [Abstract][Full Text] [Related]
12. Current controversies in data monitoring for clinical trials.
Pocock SJ
Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
[TBL] [Abstract][Full Text] [Related]
13. Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.
Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
Clin Trials; 2008; 5(4):364-5; author reply 365-6. PubMed ID: 18697851
[No Abstract] [Full Text] [Related]
14. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
Wells RJ; Gartside PS; McHenry CL
IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
[No Abstract] [Full Text] [Related]
15. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
Ellenberg SS; George SL
Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
[TBL] [Abstract][Full Text] [Related]
16. Is it ethical to keep interim findings of randomised controlled trials confidential?
Miller FG; Wendler D
J Med Ethics; 2008 Mar; 34(3):198-201. PubMed ID: 18316463
[TBL] [Abstract][Full Text] [Related]
17. Design of randomized controlled trials.
Stanley K
Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
[No Abstract] [Full Text] [Related]
18. Interim analysis in randomized trials: DAMOCLES' sword?
Besselink MG; van der Graaf Y; Gooszen HG
J Clin Epidemiol; 2010 Apr; 63(4):353-4. PubMed ID: 19959333
[No Abstract] [Full Text] [Related]
19. Randomized trials in oncology stopped early for benefit.
Wilcox RA; Djulbegovic B; Moffitt HL; Guyatt GH; Montori VM
J Clin Oncol; 2008 Jan; 26(1):18-9. PubMed ID: 18165635
[No Abstract] [Full Text] [Related]
20. The many moral responsibilities of independent data-monitoring committees.
Braillon A
Am J Bioeth; 2011 Mar; 11(3):16-7. PubMed ID: 21400378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
